Cancer

The acquisition gives Lilly access to Ajax’s experimental therapies for myeloproliferative neoplasms (MPNs), a group of rare blood cancers in which the bone marrow produces excessive blood cells.

AI Platform Accelerates Development Timeline
The team developed ISM0387 using Insilico Medicine’s Chemistry42 platform, which integrates more than 40 generative AI models to analyse complex biological and chemical data.

The procedure allowed a Dubai patient to leave the hospital within days, with his organ completely intact, an outcome that would have been impossible with traditional surgical approaches.

The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.

The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.

C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development

Histotripsy uses precisely focused ultrasound energy to destroy tumours from outside the body, eliminating the need for surgery, radiotherapy, or chemotherapy.

The two companies began collaborating in 2024 through an option and license agreement valued at up to USD 465 million, which granted Gilead access to Tubulis’ proprietary ADC platforms.

The work centres on magnetic resonance imaging (MRI), a widely used diagnostic tool that allows doctors to visualise tumours inside the body.